An Investigation to Evaluate an Over-The-Wire FFR Infusion Microcatheter (HYPEREM™IC) for Measuring Fractional Flow Reserve (FFR)

A Randomised, Crossover Investigation to Evaluate and Compare the Effectiveness, Safety and Feasibility of a Novel Dedicated Over-The-Wire FFR Infusion Microcatheter (HYPEREM™IC) for Measuring Fractional Flow Reserve (FFR) Using Intra-coronary Non-weight Adjusted Adenosine Infusion With the Standard Intra-venous Administration of Adenosine, in Subjects With Intermediate Coronary Artery Stenosis.

This is a single-blinded, randomised, crossover investigation comparing the investigational device using intra-coronary (IC) Adenosine infusion to the standard intra-venous (IV) infusion method used for obtaining FFR measurements. All subjects requiring on a clinical basis a pressure wire assessment of intermediate coronary artery stenosis(es) will be eligible to take part in the investigation.

Study Overview

• Status: Completed
• Conditions: Coronary Artery Disease
• Intervention / Treatment: Device: FFR Infusion Microcatheter and standard intra-venous (IV) infusion

Detailed Description

Coronary artery disease is the most common type of heart disease that affects millions of people worldwide. It is caused by a narrowing or blocking of the arteries (known as stenosis) due to plaque, which restricts blood flow and reduces the amount of oxygen to the heart.

Over the past decade, fractional flow reserve (FFR) measurement has been increasingly used in cardiac catheterization laboratories, providing a straightforward and readily available quantitative assessment of the functional severity of a coronary artery stenosis, as the ability of the cardiologist to discriminate between stenoses that can cause ischemia and those that are physiologically insignificant on the basis of coronary angiography alone is limited.

Measuring FFR determines the ratio between the maximum achievable blood flow in a diseased or narrowed coronary artery and the maximum blood flow in a normal coronary artery. This ratio represents the potential decrease in coronary flow distal to the coronary stenosis.

FFR is easily measured during routine coronary angiography by using a pressure wire to calculate the ratio between the coronary pressure distal to a stenosis or a diseased segment and the aortic pressure under conditions of maximum myocardial hyperemia. An FFR of 1.0 is widely accepted as normal. An FFR lower than 0.80 is generally considered to be associated with coronary ischemia and widely accepted in favour of revascularization over conservative management.

The current standard methods of measuring FFR is to insert a pressure wire into the coronary artery while the hyperaemic agent, normally adenosine, is delivered by continuous intravenous infusion via a central femoral vein, a large ante-cubital peripheral cannula or intra-coronary bolus injection.

The investigational device in this clinical investigation is an FFR catheter being developed by Diasolve Limited; a UK based medical device development company. The FFR catheter is a combined pressure wire and hyperaemic agent delivery catheter, which allows simultaneous delivery of a pressure wire and administration of the hyperaemic agent directly into the coronary ostium or most proximal section of the coronary artery, when performing a FFR measurement using currently available pressure wire systems such as Pressure Wire Certus or Prestige from St Jude Medical.

• Study Type: Interventional
• Enrollment (Actual): 41
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United Kingdom
  • Middx
    • Harrow, Middx, United Kingdom, HA1 3UJ
      • Northwick Park Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Ability and willingness to give written informed consent prior to investigation participation.
2. Has given consent to undergo hospital's diagnostic or interventional coronary procedure.
3. Male and female subjects aged 18 and over.
4. Ability to communicate well with the investigator and to comply with the requirements of the clinical investigation.

Prior to randomisation:

1. Coronary angiogram demonstrates at least one coronary stenosis of intermediate severity (40-70%), in a non-infarct related artery, which requires FFR measurement for physiological assessment.

-

Exclusion Criteria:

1. Known sensitivity to adenosine or any of its excipients
2. Technically inaccessible stenosis(es)
3. Acute ST segment elevation myocardial infarction (STEMI)
4. Haemodynamically unstable
5. Presence of any clinically significant medical condition as determined by the investigator
6. Participation in another clinical investigation within the three months prior.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: DIAGNOSTIC
• Allocation: RANDOMIZED
• Interventional Model: CROSSOVER
• Masking: SINGLE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: IV followed by IC (investigation); The patient undergoes the FFR measurement with the standard measurement first followed by FFR measurement using the FFR Infusion Microcatheter	Device: FFR Infusion Microcatheter and standard intra-venous (IV) infusion; Cross-over design where FFR is measured twice in the same lesion using standard standard intra-venous (IV) infusion and new method; Other Names: HYPEREM™IC; REF: 143836-01 GTIN: 5060420320008.; HYPERAEM
Experimental: IC (investigation) followed by IV; The patient undergoes the FFR measurement using the FFR Infusion Microcatheter measurement first followed by measurement via the standard measurement	Device: FFR Infusion Microcatheter and standard intra-venous (IV) infusion; Cross-over design where FFR is measured twice in the same lesion using standard standard intra-venous (IV) infusion and new method; Other Names: HYPEREM™IC; REF: 143836-01 GTIN: 5060420320008.; HYPERAEM

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of participants with comparable FFR ratio recordings	The FFR ratio should remain constant when measured by the standard method and the investigational device.	Intraoperative

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of participants with Adverse Events	Participants should not experience any additional adverse events during FFR ratio measurement using the investigational device than they do using the standard method.	Intraoperative
Dose of adenosine administered.	Maximum hyperaemia may be achieved with a reduced dose of adenosine using the FFR Catheter.	Intraoperative
Time to onset of maximum hyperaemia.	Maximum hyperaemia may be achieved faster using the FFR Catheter	Intraoperative

Collaborators and Investigators

• Sponsor: Diasolve Ltd
• Investigators: Principal Investigator: Ahmed Elghamaz, MB BCh, MRCP, London North West Healthcare NHS Trust; Study Chair: Paul Wenberger, Diasolve Ltd

Study record dates

Study Major Dates

• Study Start: May 1, 2016
• Primary Completion (Actual): November 1, 2016
• Study Completion (Actual): November 1, 2016

Study Registration Dates

• First Submitted: August 5, 2015
• First Submitted That Met QC Criteria: August 18, 2015
• First Posted (Estimate): August 19, 2015

Study Record Updates

• Last Update Posted (Estimate): December 14, 2016
• Last Update Submitted That Met QC Criteria: December 13, 2016
• Last Verified: December 1, 2016

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Vascular Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Coronary Disease; Coronary Artery Disease
• Other Study ID Numbers: DIAS-001-FFR

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: individual data will not be shared